-
Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Reviews on recent clinical trials 20120501
-
Comparison of three derivatization reagents for the simultaneous determination of highly hydrophilic pyrimidine antitumor agents in human plasma by LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415
-
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 20120401
-
Substrate/Product-targeted NMR monitoring of pyrimidine catabolism and its inhibition by a clinical drug.
ACS chemical biology 20120316
-
The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120301
-
Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic retinopathy.
Case reports in ophthalmology 20120101
-
Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Oncology 20120101
-
Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.
Cancer research and treatment : official journal of Korean Cancer Association 20111201
-
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
The oncologist 20111001
-
Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination.
Cancer science 20110901
-
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
American journal of clinical oncology 20110801
-
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Cancer chemotherapy and pharmacology 20110801
-
A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Cancer chemotherapy and pharmacology 20110601
-
Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Anticancer research 20110601
-
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110501
-
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 20110401
-
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
British journal of cancer 20110329
-
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
British journal of cancer 20110215
-
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Anticancer research 20110201
-
Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
PloS one 20110101
-
A case of diffuse alveolar hemorrhage associated with tegafur plus uracil and warfarin therapy.
Clinical medicine insights. Case reports 20110101
-
Pancreatic cancer: chemotherapy and radiotherapy.
North American journal of medical sciences 20110101
-
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Cancer chemotherapy and pharmacology 20101101
-
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Oncology reports 20101101
-
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20101101
-
Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 20100801
-
Gimeracil sensitizes cells to radiation via inhibition of homologous recombination.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20100801
-
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Cancer chemotherapy and pharmacology 20100701
-
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Cancer chemotherapy and pharmacology 20100501
-
[Construction of a system for proper TS-1 application].
Gan to kagaku ryoho. Cancer & chemotherapy 20100301
-
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
International journal of cancer 20100215
-
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Japanese journal of clinical oncology 20100101
-
A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report.
Clinical Medicine Insights. Oncology 20100101
-
Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.
Journal of radiation research 20100101
-
Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study.
Case reports in oncology 20100101
-
Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
International journal of radiation oncology, biology, physics 20091201
-
Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.
Cancer chemotherapy and pharmacology 20091001
-
S-1 mediates the inhibition of lymph node metastasis in oral cancer cells.
Oncology reports 20091001
-
Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20091001
-
Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
British journal of cancer 20090721
-
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.
British journal of cancer 20090707
-
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Drug metabolism and disposition: the biological fate of chemicals 20090701
-
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Annals of oncology : official journal of the European Society for Medical Oncology 20090501
-
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Anticancer research 20090501
-
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Japanese journal of clinical oncology 20090101
-
Pharmacokinetic study of S-1.
International journal of clinical pharmacology and therapeutics 20090101
-
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Cancer chemotherapy and pharmacology 20081201
-
Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.
International journal of clinical oncology 20081201
-
[Case report of gastric cancer patient who suffered life-threatening adverse events including severe myelosuppression during neoadjuvant chemotherapy with S-1 and CDDP combination].
Gan to kagaku ryoho. Cancer & chemotherapy 20080901
-
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
British journal of cancer 20080819
-
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Cancer letters 20080818
-
The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Cancer chemotherapy and pharmacology 20080801
-
[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Zhonghua yi xue za zhi 20080527
-
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Cancer science 20080501
-
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.
British journal of cancer 20080325
-
[Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings].
Gan to kagaku ryoho. Cancer & chemotherapy 20080301
-
S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.
The Korean journal of internal medicine 20080301
-
[A case of drug-induced interstitial pneumonia caused by TS-1].
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20080301
-
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Annals of oncology : official journal of the European Society for Medical Oncology 20080101
-
Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Anticancer research 20080101
-
Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Cancer chemotherapy and pharmacology 20071001
-
Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Journal of gastroenterology 20071001
-
Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
Molecular cancer therapeutics 20070801
-
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
British journal of cancer 20070604
-
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Drug metabolism and pharmacokinetics 20070601
-
Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.
British journal of cancer 20070507
-
[Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].
Gan to kagaku ryoho. Cancer & chemotherapy 20070401
-
The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
BJU international 20070301
-
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil.
Cancer chemotherapy and pharmacology 20060801
-
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oncology reports 20060801
-
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
British journal of cancer 20060605
-
[Pharmacokinetics of S-1].
Gan to kagaku ryoho. Cancer & chemotherapy 20060601
-
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Gan to kagaku ryoho. Cancer & chemotherapy 20060601
-
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
British journal of cancer 20060424
-
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Anti-cancer drugs 20060401
-
DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Anticancer research 20060101
-
Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Anticancer research 20060101
-
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Anti-cancer drugs 20051101
-
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
British journal of cancer 20051017
-
[A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Gan to kagaku ryoho. Cancer & chemotherapy 20051001
-
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Lung cancer (Amsterdam, Netherlands) 20050901
-
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Oncology reports 20050701
-
Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Lung cancer (Amsterdam, Netherlands) 20050701
-
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
British journal of cancer 20050620
-
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Gan to kagaku ryoho. Cancer & chemotherapy 20050601
-
Phase II study of S-1 in patients with advanced biliary tract cancer.
British journal of cancer 20041115
-
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
British journal of cancer 20041004
-
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
British journal of cancer 20040816
-
Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Drug metabolism and disposition: the biological fate of chemicals 20040701
-
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040615
-
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Anti-cancer drugs 20040201
-
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Oncology 20040101
-
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
British journal of cancer 20031215
-
Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Anti-cancer drugs 20031001
-
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
British journal of cancer 20030901
-
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.
British journal of cancer 20030818
-
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Cancer chemotherapy and pharmacology 20030701
-
Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma.
Anti-cancer drugs 20030701
-
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
European journal of cancer (Oxford, England : 1990) 20030601
-
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
International journal of clinical oncology 20030601
-
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 20030310
-
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 20030301
-
S-1 in gastric cancer: a comprehensive review.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101
-
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Cancer chemotherapy and pharmacology 20020701
-
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Pharmacogenetics 20020601
-
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
European journal of cancer (Oxford, England : 1990) 20020601
-
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.
British journal of cancer 20020121
-
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
The oncologist 20020101
-
Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20020101
-
Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
The Journal of pharmacology and experimental therapeutics 20010601
-
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Gan to kagaku ryoho. Cancer & chemotherapy 20010601
-
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
European journal of cancer (Oxford, England : 1990) 20010301
-
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Clinical cancer research : an official journal of the American Association for Cancer Research 20010301
-
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
Oncology 20010101
-
Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Anticancer research 20010101
